Varient provides a platform for verified rare disease patients to share quantified medication outcomes based on their genetics. Users can see what treatments have been effective for genetically similar individuals facing the same condition. The service connects patients with relevant clinical trials and reliable social resources to accelerate treatment discovery.
Funding
Funding not disclosed
Founders
Product
Problem
Individuals with rare diseases often struggle to find effective treatments due to limited research, small patient populations, and a lack of personalized information. Families often rely on anecdotal evidence and face a lengthy trial-and-error process to identify medications that alleviate symptoms, while potentially worsening others. The challenge is compounded by the difficulty in connecting with others who share similar genetic profiles and treatment experiences.
Solution
Varient is a platform designed to accelerate the path to effective treatments for individuals with rare diseases. By combining AI, genetic analysis, and community-sourced data, Varient provides personalized medication recommendations based on a user's unique genetic profile and treatment history. The platform verifies users to ensure data integrity and facilitates the sharing of treatment outcomes among genetically similar individuals, enabling informed decision-making. Varient aims to quantify medication outcomes and connect users with relevant clinical trials, while prioritizing data privacy and security.
Target Audience
The primary target audience includes individuals and families affected by rare diseases who are seeking personalized treatment options and connection with others who have similar genetic profiles.
Features
- User verification process to ensure data reliability and accuracy.
- Personalized medication recommendations based on genetic profiles and treatment histories.
- Platform for sharing and comparing treatment outcomes among verified users with similar genetic diseases.
- AI-driven analysis to identify effective treatments based on aggregated, de-identified data.
- Connection to relevant clinical trials based on individual genetic profiles and treatment needs.
- GDPR and HIPAA compliance to ensure data privacy and security.